This is just a scratch of the future ....any real good Big Pharma could see that.
Just think how this will change dmd ,need to get all these boys on drug as early as possible and all new dmd cases before 5 years old.
FDA ,Sarepta drug production meeting....
Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus Full Text
Sarepta Therapeutics, 05/20/2013
Sarepta Therapeutics, Inc., a developer of innovative RNA–based therapeutics, announced that it has initiated dosing in a Phase 1 multiple ascending dose (MAD) clinical trial of AVI–7288, the Company's lead drug candidate for the treatment of Marburg virus infection. The Phase I MAD study is designed to characterize the safety, tolerability and pharmacokinetics of AVI–7288 after repeat dosing in healthy adult volunteers. The initiation of this study follows the successfully completed Phase 1 single ascending dose study, which showed AVI–7288 was well tolerated in healthy volunteers. Sarepta is developing AVI–7288 under a contract from the U.S. Department of Defense through the Joint Project Manager Transformational Medical Technologies (JPM–TMT) Project Management Office. AVI–7288 utilizes Sarepta's advanced and proprietary PMOplus® chemistry.
Technical charts and or views are good when dealing with very large traded companies,hard to apply that to biotechs that are news driven or have up coming events or unexpected deals,partnerships,approvals ect.I would not apply that to this stock in any way.I would apply it to companies such as ge,dupont,ect
January 24, 2013
July 13, 2012
SAREPTA THERAPEUTICS, INC. (3450 Monte Villa Parkway, Suite 101Bothell, Washington, 98021, US)
IVERSEN, Patrick, L. (5902 Northwest Fair Oaks Place, Corvallis, Oregon, 97330, US)
Of or relating to an owner or ownership.
An owner; proprietor.
adjective. possessive - possessory - patent
noun. ownership - owner - property - proprietor - possession
Sarepta has developed a proprietary technology of peptide conjugated phosphorodiamidate morpholino oligomers, or our PPMO platform. Using our PPMO technology, cellular uptake of the active PMOs, as well as their potency and specificity of tissue targeting, are significantly enhanced by the conjugation of arginine-rich cell-penetrating peptide chemical moieties (CPPs) to a PMO.
Today may 17 2013 at 5.30pm......................................................................................................................................see poster abstract i posted early today.....
Sarepta Therapeutics Inc’s (SRPT) Technology Shows Dramatic Results as DMD Patients Regain Functions
May 17, 2013
Sarepta Therapeutics Inc’s (SRPT) innovative technology treating gene mutations in Duchenne muscular dystrophy patients is showing remarkable results in clinical trials, and this technology has the potential to treat other gene mutations within DMD as well as other diseases, making SRPT a promising big story in corrective medicine, says Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund.
“One of the things that’s really interesting about this company that I don’t think the market has fully digested is the fact that the way they treat Duchenne muscular dystrophy…DMD patients have a mutation in a gene called dystrophin, and their muscle cells tend to rupture and lyse… [Sarepta's technology] enables the patient to be able to make normal dystrophin like you and I have, unlike what they’ve had before. It’s nearly science fiction; real mind-blowing technology,” Kuruvilla said.
FOR MORE INFORMATION ABOUT THIS INTERVIEW CLICK HERE.
SRPT‘s treatment has already shown dramatic effects in a handful of patients that are showing incredible turnaround and a regain of function that was not possible before, Kuruvilla says. He adds that the technology is showing promise in being generalizable to other areas of DMD as well as in different diseases, placing SRPT at the forefront of one of biotech’s potentially historic breakthroughs.
“Right now, I think the market is incompletely valuing it on its lead indication, this 15% of DMD subset, but if you begin to think about, and have a little bit of imagination about, other forms of Duchenne muscular dystrophy and other diseases, this becomes one of the most significant technology platforms that biotech has seen in a number of years,” Kuruvilla said. “This can be one of the big stories not just in DMD, but in corrective medicine and truly disease-modifying therapy to come around in a long time.”
item 2 being presented today as well
Bo Wu, Caryn Cloer, Stephanie Milazi, Mona Shaban, Sapana N. Shah, Peijuan Lu, Hong M. Moulton, Qi Long Lu. McColl-Lockwood Laboratory for Muscular Dystrophy Research, Carolinas Medical Center, Charlotte, NC; Department of Biomedical Sciences, Oregon State University, Corvallis, OR